P = 0.0007) g/L 16 (Mean differences [95% CI] in the changes from baseline between GLP-1-based therapy and control patients)
A New Class of Triple Agonist Retatrutide (LY3437943) is a groundbreaking investigational medication developed by Eli Lilly, designed to combat obesity and type 2 diabetes
Insurance Coverage Predictions CagriSema (Advantage: Semaglutide Component): Leverages Wegovy's established coverage "Combination of proven medication + new molecule" easier sell to insurers Predicted coverage: 50-60% of commercial plans initially Retatrutide (Challenge: Novel Molecule): Entirely new drug class, no established coverage Higher efficacy but also higher side effects Will likely require trial-and-failure of cheaper options Predicted coverage: 40-50% of commercial plans initially Clinical Trial Populations and Indications CagriSema: Diabetes Focus REDEFINE-1: Obesity without diabetes (3,417 participants) REDEFINE-2: Obesity WITH type 2 diabetes (1,206 participants) REIMAGINE Program: Additional diabetes-focused trials Advantage: Strong diabetes data positions CagriSema for dual obesity + diabetes indications, like tirzepatide (Mounjaro/Zepbound)
Make it a habit Choose a wake-up time you can realistically maintain throughout the week
Log Everything, Immediately: Get a lab notebook or create a spreadsheet
If they quit, weight can return quickly
%20(1).png)
